Medexus Pharmaceuticals Inc
TSX:MDP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Medexus Pharmaceuticals Inc
TSX:MDP
|
CA |
|
M
|
Mycron Steel Bhd
KLSE:MYCRON
|
MY |
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
ID |
|
A
|
Aritzia Inc
OTC:ATZAF
|
CA |
|
S
|
Shanghai Fudan Forward S&T Co Ltd
SSE:600624
|
CN |
Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which provides healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease and pediatrics. The company is headquartered in Bolton, Ontario and currently employs 79 full-time employees. The company went IPO on 2012-03-03. The firm is a North American focused, specialty pharmaceutical business that operates through two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada, a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. Medexus Pharma USA, a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States (U.S). The firm is focused on the therapeutic areas of auto-immune disease, hematology, pediatrics, dermatology and allergy. The firm's products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases. The company also offers IXINITY, a medicine for use in patients 12 years of age or older with Hemophilia B and Rupall, an allergy medication.
Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which provides healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease and pediatrics. The company is headquartered in Bolton, Ontario and currently employs 79 full-time employees. The company went IPO on 2012-03-03. The firm is a North American focused, specialty pharmaceutical business that operates through two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada, a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. Medexus Pharma USA, a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States (U.S). The firm is focused on the therapeutic areas of auto-immune disease, hematology, pediatrics, dermatology and allergy. The firm's products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases. The company also offers IXINITY, a medicine for use in patients 12 years of age or older with Hemophilia B and Rupall, an allergy medication.
GRAFAPEX Launch: Early commercial performance of GRAFAPEX exceeded prelaunch expectations, with strong January demand and increasing hospital formulary adoption.
Revenue: Q3 fiscal 2026 net revenue was $25.3 million, down from $30 million a year earlier, due mainly to reduced Rupall sales and the return of Gleolan.
Profitability: The company posted positive operating income and adjusted EBITDA for the third consecutive quarter since GRAFAPEX’s approval and launch.
Gross Margin: Gross margin improved to 53.6% from 50.7% last year, and management expects further gains as GRAFAPEX ramps up.
Cash Flow: Operating cash flow increased to $7.8 million for the quarter, and average quarterly cash flow since GRAFAPEX launch has been $4.3 million.
Guidance: GRAFAPEX is expected to generate $11–12 million in net revenue for fiscal 2026 and $3–4 million in Q4, with accretive cash flow starting in Q4.
Portfolio Dynamics: The base business is seen as stable, with GRAFAPEX growth expected to drive future performance.
